Overview
International law firm McDermott Will & Emery advised GeNeuro, a Swiss company listed on the regulated market of Euronext Paris, on its €17.5 million capital increase realized by way of an international private placement of new shares to qualified institutional investors.
Bryan, Garnier & Co Limited acted as Sole Book Runner on the private placement and a prospectus was approved on January 31, 2020 by the French Autorité des marchés financiers in relation to the listing of the newly issued shares.
GeNeuro is a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases.
McDermott Will & Emery’s team in Paris was led by partner David Revcolevschi.
In Geneva, Gantey advised GeNeuro on the Swiss law aspects with partners Christophe Buchwalder and Natasa Markovic leading.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
